Scripps Research Logo

News Release

TSRI and STSI Scientists Use ‘Molecular Autopsies’ to Find Clues to Sudden Death

Findings Could Help Living Relatives Understand Their Own Risk

LA JOLLA, CA – October 11, 2016 – Sudden death strikes approximately 11,000 people under age 45 in the U.S. every year, leaving living relatives with troubling questions about their own risk. Unfortunately, with many conditions—such as sudden infant death syndrome (SIDS) and sudden cardiac death (SCD)—the cause of death is not always apparent after a traditional clinical autopsy.

Now a new study led by scientists at The Scripps Research Institute (TSRI) and the Scripps Translational Science Institute (STSI) suggests that “molecular autopsies” may be valuable in detecting gene mutations responsible for a sudden death. The research, while preliminary, could help doctors alert living family members to hidden health conditions.

The research, led by Ali Torkamani, assistant professor of Molecular and Experimental Medicine at TSRI and assistant professor and director of Genome Informatics at STSI, was published October 11, 2016, in the Journal of the American Medical Association (JAMA).

“The key takeaway is that molecular autopsy, when performed in a prospective and family-based manner, can reveal the genetic cause of sudden death in a variety of conditions and provide useful information regarding risk to living relatives,” Torkamani said.

For the study, the researchers sequenced samples from 25 sudden death cases. To assess possible inherited mutations, the team also sequenced samples from the deceased patients’ parents in nine of the cases.

This analysis provided clues that weren’t apparent in traditional clinical autopsies. In four cases, the researchers found that a genetic mutation was a “likely” cause of death, and they found six more cases where a mutation was a “plausible” cause of death. In seven cases, a mutation was found to be a “speculative” cause of death.

Overall, molecular autopsies uncovered a likely or plausible cause of death in 40 percent of cases. Interestingly, many of the findings were variants of genes inherited from relatives who had not suffered from the syndrome.

The researchers believe identifying possible genetic mutations behind sudden death could help doctors and family members plan for clinical follow-ups, preventative measures and active surveillance to watch for symptoms—even in cases where the mutation was just a “speculative” cause of death.

The researchers said larger studies are needed to collect enough data to provide living relatives with a better idea of their risk.

In addition to Torkamani, authors of the study, “Molecular Autopsy for Sudden Unexpected Death,” included Eric J. Topol, Evan D. Muse, Emily G. Spencer and Manuel Rueda of TSRI and STSI; and Glenn N. Wagner and Jonathan R. Lucas of the Medical Examiner Department of San Diego County.

The study was supported by a National Institutes of Health and National Center for Advancing Translational Sciences clinical and translational science award (5-UL1-RR025774) and Scripps Genomic Medicine (grants U01HG006476 and U54GM114833).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academy of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

About Scripps Translational Science Institute

The Scripps Translational Science Institute aims to replace traditional one-size-fits-all medicine with individualized health care by leveraging the power of genomic medicine, wireless health sensors and mobile phone applications, and other digital medicine technologies. In a unique collaboration, STSI merges the considerable biomedical science expertise of The Scripps Research Institute with Scripps Health’s exceptional patient care and clinical research capabilities. STSI is supported in part by the National Institutes of Health Clinical and Translational Science Award. For more information, visit www.stsiweb.org.

# # #

For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8118
press@scripps.edu


Ali Torkamani is assistant professor of Molecular and Experimental Medicine at The Scripps Research Institute and director of Genome Informatics at the Scripps Translational Science Institute. (High-res image)


FOR MORE INFORMATION